Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease
Recruiting
Global Blood Therapeutics
Phase 2
2016-05-18
This study consists of four parts, Parts A, B, C, and D. Part A is a single dose
pharmacokinetic (PK) study in pediatric participants with Sickle Cell Disease. Part B is a
multiple dose, safety, exploratory, efficacy, and PK study in adolescent Sickle Cell Disease
participants who were 12-17 years of age. Part C is a multiple dose, safety, tolerability,
and PK study, which includes the assessment of hematological effects and the effect on TCD
flow velocity of voxelotor in pediatric participants with Sickle Cell Disease who are 4 to 17
years of age. Part D is a multiple dose, safety, tolerability, and PK study, which will
examine the hematological effects of voxelotor in pediatric participants with Sickle Cell
Disease who are between 9 months to < 4 years of age.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
